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Chronic granulomatous disease (CGD) is a primary immuno-
deﬁciency caused by mutations of the phagocytic nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase. Autosomal
recessive p47phox-deﬁcient CGD (p47phox CGD) is the second
most frequent form of the disease in western countries, and
more than 94% of patients have a disease-causing dinucleotide
deletion (DGT) in the neutrophil cytosolic factor 1 (NCF1)
gene. The DGT mutation is most likely transferred onto the
NCF1 from one of its two pseudogenes co-localized on the
same chromosome. The presence of NCF1 pseudogenes in
healthy individuals makes the genetic diagnostics of DGT
p47phox CGD challenging, as it requires the distinction between
DGT in NCF1 and in the two pseudogenes. We have developed
a diagnostic tool for the identiﬁcation of p47phoxCGD based on
PCR co-ampliﬁcation of NCF1 and its pseudogenes, followed
by band intensity quantiﬁcation of restriction fragment length
polymorphism products. The single-day, reliable p47phox CGD
diagnostics allow for robust discrimination of homozygous
DGT p47phox CGD patients from heterozygous carriers and
healthy individuals, as well as for monitoring gene therapy
efﬁcacy.
INTRODUCTION
Chronic granulomatous disease (CGD) is a primary immunodeﬁ-
ciency of phagocytes, leading to recurrent severe bacterial and fungal
infections due to impaired reactive oxygen species (ROS) production
by the nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dase complex.1 Disease-causing mutations are found in all NADPH
oxidase subunits gp91phox, p47phox, p67phox, p22phox, and p40phox. In
western countries, p47phox deﬁciency (p47phox CGD) is the second
most frequent form of CGD. p47phox CGD is genetically exceptional,
as 97% of patients share the same mutation, a dinucleotide deletion
(DGT) within the GTGT sequence in exon 2 of the neutrophil cyto-
solic factor 1 (NCF1) gene.2 On chromosome 7, the NCF1 gene is
accompanied by two pseudogenes (NCF1B and NCF1C) with 99.5%
sequence homology to NCF1 (Figures 1A–1C).
TheDGTmutation is also present in both pseudogenes, in healthy in-
dividuals, in CGD patients, and in carriers. NCF1 DGT results from
unequal cross-over events between NCF1 and one of its pseudogenes
during DNA replication or repair, leading to partial pseudogene
sequence transfer, includingDGT, onto theNCF1 gene.3–5 Genetic di-
agnostics of DGT p47phox CGD are challenging, as it requires the
distinction betweenDGT inNCF1 and in the pseudogenes. Currently,
diagnosis of DGT p47phox CGD relies on the gene-scan method,6
which is based on the comparison of ﬂuorescence intensities of short
co-ampliﬁed sequences of NCF1 and its pseudogenes, which differ in
size by the 2-nt of the DGT mutation. Other diagnostic methods are
allele-speciﬁc hybridization5 and determination of the DGT:GTGT
ratio by the TaqMan copy number variation (CNV) assay.7
RESULTS AND DISCUSSION
We have developed a novel diagnostic tool for the identiﬁcation of
DGT p47phox CGD based on PCR co-ampliﬁcation of NCF1 and its
pseudogenes, followed by band intensity quantiﬁcation of restriction
fragment length polymorphism products (Figures 1B–1G). This
1-day method determines the NCF1 gene CNV by quantiﬁcation of
GTGT content in the NCF1 gene and pseudogene loci, and thus it de-
tects the presence or absence of the DGTmutation within NCF1 gene
and pseudogene alleles. It can be established in any molecular biology
laboratory, and it allows for the robust discrimination of homozygous
DGT p47phox CGD patients from heterozygous carriers and healthy
individuals for rapid diagnostic purposes, as well as for the moni-
toring of NCF1 genome-editing-based gene therapy.8
For quantiﬁcation of the GTGT content, corresponding NCF1,
NCF1B, and NCF1C sequences were co-ampliﬁed in one PCR reac-
tion, digested, and visualized by PAGE or agarose electrophoresis
(Figures 2A and 2B; detailed characterization of bands in polyacryl-
amide gel in Figures S2–S6). PCR-restriction fragment length poly-
morphism (RFLP) analysis was performed for 60 healthy individuals,
10 conventionally diagnosed DGT p47phox CGD patients, and 8
conventionally diagnosed DGT p47phox CGD carriers (see Table S1).
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Figure 1. PCR-RFLP Analysis of NCF1 Loci
(A) Co-amplified fragments of the NCF1 gene and pseudogenes. Positions of the GT-dinucleotide, 20-nt repeat, BsrG1 and Pst1 restriction sites, and primer-binding sites
(forward and reverse) are shown. (B) In healthy individuals and (C) in patients with the DGTmutation in NCF1, the PCR co-amplification of NCF1 (correct, blue; mutated, red)
(legend continued on next page)
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The co-ampliﬁcation PCRproducts spanned theNCF1 gene and pseu-
dogene GTGT locus within exon 2, as well as the surrounding intronic
regions containing one or two repeats of a 20-nt sequence (1 20 nt or
2  20 nt; Figure 1A). Figure 1 displays possible DNA sequence vari-
ations of these loci, their conﬁguration on chromosome 7, correspond-
ing PCR co-ampliﬁcation products, as well as PCR-RFLP results. CGD
patients with homozygousDGTmutation inNCF1 can be identiﬁed by
electrophoresis based on the absence of the 169-bp band (Figures 1C,
1F, and 2A, and 2B). The intensity of the 169-bp band was substan-
tially weaker in heterozygous carriers. The absence of the 181-bp
band (Figure 2, control 3) was observed in individuals who had two
copies of the 20-nt repeat in intron 2 in allNCF1 gene and pseudogene
alleles, a genotype that may be observed in healthy individuals. Calcu-
lation of the GTGT content (Figure 1G) allowed for the differentiation
betweenNCF1DGTmutation carriers and healthy individuals. Repre-
sentative PCR-RFLP samples developed byPAGE and agarose electro-
phoresis (Figures 2A–2C) compare controls (healthy individuals with
GTGT in two NCF1 alleles and different 20-nt intronic repeat
numbers), X-CGD and autosomal recessive CGD NCF2 (gp91phox
and p67phox deﬁciency, respectively), twoNCF1DGT carriers (Carrier
DGT #1 and CarrierDGT #2), an induced pluripotent stem cell (iPSC)
NCF1 DGT cell line,9 a human acute myeloid leukemia cell line PLB-
985 (wild-type), and a PLB-985 NCF1 DGT cell line.8
The median GTGT content in 55 healthy individuals who carried two
NCF1 gene alleles with the GTGT sequence and theDGTmutation in
all four pseudogene alleles (Control ratio 1:2; Figure S1A) was 0.29 in
the polyacrylamide gel and 0.20 in the agarose gel. With NCF1 allele
PCR co-ampliﬁcation, followed by single-molecule real-time (SMRT)
sequencing (Table S1), we identiﬁed ﬁve healthy individuals with two
functional NCF1 alleles with GTGT sequence plus one of four pseu-
dogene alleles with GTGT sequence (Control ratio 1:1; Figure S1B). In
these individuals, the determined GTGT content values were 0.49 and
0.29 in polyacrylamide and in agarose gel, respectively. The observed
results in agarose gels were lower than theoretical values expected by
the genetic background, which may be explained by a partial loss of
signal intensity in the thick agarose gels. GTGT content values estab-
lished for 8 DGT p47phox CGD carriers, in which one NCF1 allele
carries theDGTmutation, was 0.10 in polyacrylamide gel (Figure 2D)
and 0.08 in agarose gel (Figure 2E; data for individual samples and
statistics in Table S1).
The results of the PCR-RFLP analysis were conﬁrmed by SMRT
sequencing: undigested pools of barcoded co-ampliﬁcation PCR
products (Figures 1A and 1B) were sequenced, and the frequencies
of GTGT signature-containing reads were calculated (Figure 2F;
Table S1). GTGT sequence was identiﬁed in 27% of reads from
healthy individuals with two GTGT-carrying NCF1 alleles (Control
ratio 1:2), in 37% of reads from healthy individuals with GTGTwithin
two NCF1 alleles and one of four pseudogene alleles (Control ratio
1:1), and in 16% of reads from NCF1 DGT carriers. Percentage differ-
ences in the GTGT signature-containing reads were statistically
signiﬁcant, and they allowed for the discrimination of healthy indi-
viduals from NCF1 DGT carriers and CGD patients.
In conclusion, we propose a package of complementary methods to be
used for single-day reliable p47phox CGD diagnostics, based on PCR-
RFLP, giving comparable results to SMRT sequencing. Furthermore,
the PCR-RFLP diagnostic method represents an attractive alternative
to the existing methods used in CGD diagnostics in terms of appli-
ance requirements and costs per tested sample (Table 1). In addition
to diagnostics, both methods can be also effectively applied for the
assessment of correction of the DGT mutation upon genome-edit-
ing-based gene therapy.
MATERIALS AND METHODS
DNA Isolation and PCR Amplification
Sample processing was covered by ethical vote KEK ZH 2015/0135,
BASEC-Nr. PB_2016-02202. Genomic DNA from healthy individ-
uals, diagnosed DGT p47phox CGD patients, and their family mem-
bers was isolated using DNeasy Blood & Tissue Kit (QIAGEN, Hom-
brechtikon, Switzerland). The 411- to 433-bp fragments of NCF1,
NCF1B, and NCF1C genes were PCR co-ampliﬁed using published
PCR primers6 (Microsynth, Balgach, Switzerland). Phusion High-Fi-
delity DNA Polymerase and deoxyribonucleotides (dNTPs) were
from Thermo Fisher Scientiﬁc (Reinach, Switzerland). PCR reaction
included GC 10 buffer, dNTPs (200 mM each), primers (240 nM
each), 0.04 U/mL Phusion High-Fidelity DNA Polymerase, and
2.5 ng/mL DNA. Initial 3-min denaturation (95C) was followed by
36–40 cycles of denaturation (95C, 30 s), annealing (65C, 30 s),
and elongation (72C, 15 s) and ﬁnal elongation (72C, 3 min).
Determination of the GTGT Content by RFLP
The PCR co-ampliﬁcation products of NCF1, NCF1B, and NCF1C
were digested with BsrG1 and Pst1 (New England Biolabs, Frankfurt
am Main, Germany) (37C, 180 min), followed by enzyme inactiva-
tion (80C, 20 min) (Figures 1A–1C). The digestion fragments were
developed in a 7.5% polyacrylamide (ratio 29:1) gel or a 5% (w/v)
agarose gel stained with GelRed Nucleic Acid Gel Stain (Biotum,
Fremont, CA, USA) and visualized using Gel Logic 100 Imaging
System (Kodak, Eysins, Switzerland). Band intensities were quantiﬁed
with ImageJ software.10 For determination of the GTGT content
and its pseudogenes (red) results in a mixture of PCR products with a defined stoichiometry. In the majority of individuals, co-amplified PCR products differ by 2-nt of the GT-
dinucleotide locus, and in 20-nt of the intronic 20-nt repeat sequence. A significant fraction of the mixture comprises cross-hybridized PCR products derived from NCF1 and
the pseudogenes (marked with an asterisk) (Figures S2–S6). BsrG1 and Pst1 restriction digestion leads to the appearance of up to seven different restriction fragments in
healthy individuals (A) and up to five fragments in patients with DGT deletion in NCF1 (B) (Figure 2A). (D–F) Typical densitometry images of digested fragments in a poly-
acrylamide gel of (D) a healthy individual with NCF1 gene to pseudogene ratio 1:2 (Control 1:2), (E) a carrier of the DGT mutation with NCF1 gene to pseudogene ratio 1:5
(Carrier DGT), and (F) a DGT p47phox CGD patient (CGD NCF1 DGT). (G) Size-normalized band intensities of 169-, 181-, and 201-bp fragments (B–F, blue) are used for
calculation of the GTGT content and for identification of DGT p47phox CGD patients and DGT mutation carriers.
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(Figure 1G), RFLP band intensities of 169-, 181-, and 201-bp BsrG1/
Pst1 digestion products (Figures 1D–1F, 2A, and 2B) were size
normalized by dividing band intensities by their length (number of
base pairs). The size-normalized band intensity of the 169-bp band
was divided by the sum of normalized band intensities of the 181-
and 201-bp bands (Figure 1G).
SMRT Sequencing
PCR co-ampliﬁcation products of theNCF1 gene and its pseudogenes
were produced using individually barcoded Fwd1 primers, utilizing
PCR conditions described above. PCR products were puriﬁed using
the QIAquick Gel Puriﬁcation Kit (QIAGEN). 20 ng gel-puriﬁed bar-
coded PCR products of individual subjects were pooled and analyzed
with SMRT sequencing11 by Functional Genomics Center Zurich,
ETH/University of Zurich, Switzerland, as described.8
Statistical Analysis
The Kruskal-Wallis tests with post hoc Dunn’s multiple comparison
tests were performed using IBM SPSS Statistics version 23.0 (IBM,
Armonk, NY, USA).
Figure 2. GTGT Content Determination by PCR-RFLP
(A) PAGE and (B) agarose gel electrophoresis of BsrG1- and Pst1-digested PCR co-
amplification products of the NCF1 loci (Figures 1B and 1C; full gel images available
in Figure S7). The band of size 63-bp is not displayed in the gels. Bands of 201-,
181-, and 169-bp (blue box) were used to determine the GTGT content (Figure 1G).
(C) List of samples presented in (A) and (B). Controls 1–3, GTGT sequence in both
NCF1 gene alleles; Control 1, a single 20-nt intronic repeat (1  20 nt) in two and a
double 20-nt repeat (2  20 nt) in four NCF1 alleles; Control 2, 1  20 nt in three of
six NCF1 alleles whereas 2 20 nt in three remaining NCF1 alleles; Control 3, all six
NCF1 alleles contain the 2 20 nt; X-CGD and CGDNCF2, gp91phox- and p67phox-
deficient CGD, respectively; carrier DGT, heterozygous DGT mutation in NCF1;
iPSC NCF1 DGT, induced pluripotent stem cell line with a homozygous DGT mu-
tation in NCF1 (see Jiang et al.9); human acute myeloid leukemia cell line PLB-985
(wild-type); and a cellular model of DGT p47phox CGD, PLB-985 NCF1 DGT (see
Wrona et al.8). (D and E) The GTGT content in polyacrylamide (D) and agarose gels
(E). (F) The GTGT content determined by SMRT sequencing. Control ratio 1:2
(Figure S1A), the GTGT sequence in NCF1 and the DGT in NCF1B and NCF1C;
Control ratio 1:1 (Figure S1B), the GTGT sequence inNCF1 and in one of four NCF1
pseudogene alleles. (D–F) Horizontal lines represent median values. *p < 0.01, n,
number of samples.
Table 1. Comparison of Methods Used for DGT p47phox CGD Diagnostics
Method
Time
(Days)
Primer
Labeling Equipment Cost
PCR-RFLP (new
method described
in this article)
1* no*
PAGE or agarose
electrophoresis
system*
*
Gene scan 1*
yes (ﬂuorescently
labeled)**
DNA sequencer*** ***
Allele-speciﬁc
hybridization
2**
yes (32P
oligonucleotides)**
autoradiography
equipment*
**
TaqMan CNV 1*
yes (ﬂuorescently and
MGB-labeled probe)***
qPCR instrument*** ***
Asterisks indicate time and resource requirements (*lowest, ***highest). MGB, minor
groove binder.
www.moleculartherapy.org
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